The Impact of Worsening Heart Failure in the United States

Heart Failure Clinics

Volumn 11, Issue 4, 2015, Pages 603-614

  Cooper, Lauren B ^a   DeVore, Adam D ^a   Michael Felker, G ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Clinical trials; Medications; Outcomes; Worsening heart failure

Indexed keywords

DOPAMINE; FUROSEMIDE; LEVOSIMENDAN; NESIRITIDE; ROLOFYLLINE; SERELAXIN; TEZOSENTAN; URODILATIN;

ACUTE HEART FAILURE; CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; HEALTH CARE COST; HEART FAILURE; HOSPITAL READMISSION; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNITED STATES; ACUTE DISEASE; ECONOMICS; HOSPITALIZATION; REGISTER; STATISTICS AND NUMERICAL DATA;

ACUTE DISEASE; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HOSPITALIZATION; HUMANS; INCIDENCE; REGISTRIES; UNITED STATES;

EID: 84942297005     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2015.07.004     Document Type: Review

References (40)

1. Mozaffarian D., Benjamin E.J., Go A.S., et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015, 131(4):e29-e322.
2. Ramirez A., Abelmann W.H. Cardiac decompensation. N Engl J Med 1974, 290(9):499-501.
3. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013, 128(16):e240-e327.
4. Solomon S.D., Dobson J., Pocock S., et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007, 116(13):1482-1487.
5. Setoguchi S., Stevenson L.W., Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007, 154(2):260-266.
6. Cooper L.B., Hammill B.G., Sharma P.P., et al. Differences in health care utilization and outcomes based on timing of in-hospital worsening heart failure. Circ Cardiovasc Qual Outcomes 2015, 8(Suppl 2):A324.
7. Kelly JP, Mentz RJ, Hasselblad V, et al. Worsening heart failure during hospitalization for acute heart failure: insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). American Heart Journal, in press.
8. Cotter G., Kaluski E., Stangl K., et al. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail 2004, 6(5):601-609.
9. Weatherley B.D., Milo-Cotter O., Felker G.M., et al. Early worsening heart failure in patients admitted with acute heart failure-a new outcome measure associated with long-term prognosis?. Fundam Clin Pharmacol 2009, 23(5):633-639.
10. Torre-Amione G., Milo-Cotter O., Kaluski E., et al. Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome. J Card Fail 2009, 15(8):639-644.
11. Teerlink J.R., McMurray J.J., Bourge R.C., et al. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J 2005, 150(1):46-53.
12. McMurray J.J., Teerlink J.R., Cotter G., et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007, 298(17):2009-2019.
13. Massie B.M., O'Connor C.M., Metra M., et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010, 363(15):1419-1428.
14. Hernandez A.F., O'Connor C.M., Starling R.C., et al. Rationale and design of the acute study of clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). Am Heart J 2009, 157(2):271-277.
15. O'Connor C.M., Starling R.C., Hernandez A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011, 365(1):32-43.
16. Felker G.M., Lee K.L., Bull D.A., et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011, 364(9):797-805.
17. Packer M., Colucci W., Fisher L., et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013, 1(2):103-111.
18. Ponikowski P., Metra M., Teerlink J.R., et al. Design of the RELAXin in acute heart failure study. Am Heart J 2012, 163(2):149-155.e1.
19. Teerlink J.R., Cotter G., Davison B.A., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013, 381(9860):29-39.
20. Chen H.H., Anstrom K.J., Givertz M.M., et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013, 310(23):2533-2543.
21. Felker G.M., Butler J., Collins S.P., et al. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). JACC Heart Fail 2015, 3(3):193-201.
22. Anker S.D., Ponikowski P., Mitrovic V., et al. Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J 2015, 36(12):715-723.
23. European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of acute heart failure. London: 2015.
24. FDA. FDA Briefing Document, Cardiovascular and Renal Drugs Advisory Committee Meeting. March 27, 2014.
25. Cotter G., Dittrich H.C., Davison Weatherley B., et al. The PROTECT Pilot Study: a Randomized, Placebo-Controlled, Dose-Finding Study of the Adenosine A1 Receptor Antagonist Rolofylline in Patients With Acute Heart Failure and Renal Impairment. J Card Fail 2008, 14(8):631-640.
26. Cotter G., Metra M., Davison B.A., et al. Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. Eur J Heart Fail 2014, 16(12):1362-1371.
27. Metra M., O'Connor C.M., Davison B.A., et al. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. Eur Heart J 2011, 32(12):1519-1534.
28. Metra M., Teerlink J.R., Felker G.M., et al. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. Eur J Heart Fail 2010, 12(10):1130-1139.
29. Davison B.A., Metra M., Cotter G., et al. Worsening Heart Failure Following Admission for Acute Heart Failure: a Pooled Analysis of the PROTECT and RELAX-AHF Studies. JACC Heart Fail 2015, 3(5):395-403.
30. Mentz R.J., Metra M., Cotter G., et al. Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. Eur J Heart Fail 2015, 17(7):697-706.
31. DeVore A.D., Hammill B.G., Sharma P.P., et al. In-hospital worsening heart failure and associations with mortality, readmission, and healthcare utilization. J Am Heart Assoc 2014, 3(4):e001088.
32. Allen L.A., Hernandez A.F., O'Connor C.M., et al. End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol 2009, 53(24):2248-2258.
33. Felker G.M., Pang P.S., Adams K.F., et al. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail 2010, 3(2):314-325.
34. Gheorghiade M., Adams K.F., Cleland J.G., et al. Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. Am Heart J 2009, 157(6):957-970.
35. Butler J., Fonarow G.C., O'Connor C., et al. Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. Am Heart J 2015, 169(3):305-314.
36. Teerlink J.R., Metra M., Felker G.M., et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009, 373(9673):1429-1439.
37. Cotter G., Metra M., Weatherley B.D., et al. Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure-association with signs and symptoms, hospitalization duration, and 60-day outcomes. Cardiology 2010, 115(1):29-36.
38. Metra M., Cotter G., Davison B.A., et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013, 61(2):196-206.
39. O'Connor C.M., Mentz R.J., Cotter G., et al. The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. Eur J Heart Fail 2012, 14(6):605-612.
40. DeVore A.D., Greiner M.A., Sharma P.P., et al. The ADHERE Risk Model for in-hospital worsening heart failure. Circ Cardiovasc Qual Outcomes 2015, 8(Suppl 2):A168.